Thermo Fisher Scientific Expands Biotech and Diagnostic Portfolio With New Instruments and CDMO Services
SHERIDAN, WYOMING - April 13, 2026 - Thermo Fisher Scientific continues to broaden its life science and laboratory portfolio across bioprocessing, molecular diagnostics, and gene therapy, positioning itself as an integrated supplier for biotechnology and biopharma customers from discovery through commercial manufacturing. The company's German operations offer the full product and service stack - from TaqMan Real-Time PCR assays and Orbitrap Astral mass spectrometers to CDMO and CRO services under the Patheon and PPD brands. New instrument releases targeting water and nutrient analysis, IVD-compliant thermal cycling, and high-resolution mass spectrometry signal continued capital investment in laboratory hardware. The breadth of this portfolio expansion has direct implications for procurement, R&D, and quality teams operating in regulated life science environments.